Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 4
1952 4
1953 4
1954 5
1955 3
1956 4
1958 2
1959 5
1960 3
1961 4
1962 12
1963 12
1964 17
1965 14
1966 21
1967 24
1968 21
1969 33
1970 32
1971 28
1972 22
1973 21
1974 25
1975 40
1976 25
1977 35
1978 53
1979 46
1980 53
1981 69
1982 50
1983 59
1984 53
1985 72
1986 79
1987 81
1988 89
1989 122
1990 123
1991 102
1992 108
1993 130
1994 121
1995 119
1996 120
1997 132
1998 154
1999 117
2000 128
2001 133
2002 148
2003 115
2004 161
2005 139
2006 146
2007 175
2008 156
2009 173
2010 174
2011 205
2012 216
2013 206
2014 235
2015 249
2016 258
2017 307
2018 259
2019 279
2020 392
2021 464
2022 423
2023 267

Text availability

Article attribute

Article type

Publication date

Search Results

7,189 results

Results by year

Filters applied: . Clear all
Page 1
Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T, Fukuokaya W, Shim SR, Mostafaei H, Motlagh RS, Quhal F, Laukhtina E, Pallauf M, Pradere B, Kimura T, Egawa S, Shariat SF. Yanagisawa T, et al. Among authors: mori k. Eur Urol. 2022 Dec;82(6):584-598. doi: 10.1016/j.eururo.2022.08.002. Epub 2022 Aug 19. Eur Urol. 2022. PMID: 35995644 Free article. Review.
Scleral PERK and ATF6 as targets of myopic axial elongation of mouse eyes.
Ikeda SI, Kurihara T, Jiang X, Miwa Y, Lee D, Serizawa N, Jeong H, Mori K, Katada Y, Kunimi H, Ozawa N, Shoda C, Ibuki M, Negishi K, Torii H, Tsubota K. Ikeda SI, et al. Among authors: mori k. Nat Commun. 2022 Oct 10;13(1):5859. doi: 10.1038/s41467-022-33605-1. Nat Commun. 2022. PMID: 36216837 Free PMC article.
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, Yoshizawa A, Nakamura K, Yano Y, Nishimura K, Nishio K, Nakamori K, Iwatani K, Yamamoto S, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H. Uchimoto T, et al. Among authors: mori k. BJU Int. 2023 Apr;131(4):477-485. doi: 10.1111/bju.15893. Epub 2022 Sep 26. BJU Int. 2023. PMID: 36098556
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial.
Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, Umetsu M, Akamatsu D, Nishimoto Y, Sato Y, Takada T, Jujo K, Minami Y, Ogihara Y, Dohi K, Fujita M, Nishikawa T, Ikeda N, Hashimoto G, Otsui K, Mori K, Sueta D, Tsubata Y, Shoji M, Shikama A, Hosoi Y, Tanabe Y, Chatani R, Tsukahara K, Nakanishi N, Kim K, Ikeda S, Mo M, Yoshikawa Y, Kimura T; ONCO DVT Study Investigators. Yamashita Y, et al. Among authors: mori k. Circulation. 2023 Nov 21;148(21):1665-1676. doi: 10.1161/CIRCULATIONAHA.123.066360. Epub 2023 Aug 28. Circulation. 2023. PMID: 37638968 Clinical Trial.
A predictive model for acute exacerbation of idiopathic interstitial pneumonias.
Karayama M, Aoshima Y, Suzuki T, Mori K, Yoshizawa N, Ichikawa S, Kato S, Yokomura K, Kono M, Hashimoto D, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Goshima S, Inui N, Suda T. Karayama M, et al. Among authors: mori k. Eur Respir J. 2023 May 5;61(5):2201634. doi: 10.1183/13993003.01634-2022. Print 2023 May. Eur Respir J. 2023. PMID: 36822633 Free PMC article.
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, Toyozawa R, Miura S, Fujimoto D, Nakagawa K, Yamamoto N, Takahashi T. Kenmotsu H, et al. Among authors: mori k. J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27. J Thorac Oncol. 2022. PMID: 35636696 Free article. Clinical Trial.
A gender-related dichotomy in bladder cancer.
Cimadamore A, Teoh JY, DI Trapani E, Krajewski W, Tan WS, Mori K, Del Giudice F, Carrion DM, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Cimadamore A, et al. Among authors: mori k. Minerva Urol Nephrol. 2022 Jun;74(3):376-378. doi: 10.23736/S2724-6051.22.04954-0. Minerva Urol Nephrol. 2022. PMID: 35607787 Free article. No abstract available.
Reply to Binghao Zhao et al.
Kenmotsu H, Mori K, Nakagawa K, Yamamoto N, Takahashi T. Kenmotsu H, et al. Among authors: mori k. J Thorac Oncol. 2022 Sep;17(9):e77-e79. doi: 10.1016/j.jtho.2022.07.002. J Thorac Oncol. 2022. PMID: 36031293 Free article. No abstract available.
Seronegative Full-house Nephropathy with Crohn's Disease.
Uedono H, Tsuda A, Ueno N, Natsuki Y, Nakaya R, Nishide K, Machiba Y, Fujimoto K, Nakatani S, Mori K, Emoto M. Uedono H, et al. Among authors: mori k. Intern Med. 2022 Dec 1;61(23):3553-3558. doi: 10.2169/internalmedicine.8820-21. Epub 2022 May 7. Intern Med. 2022. PMID: 35527024 Free PMC article.
7,189 results